Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Sulzer's Roost

This article was originally published in The Gray Sheet

  • News

Executive Summary

Resignation of Ueli Roost as Chairman of Sulzer Medica and of parent firm Sulzer Ltd is effective immediately. A March 26 announcement cites the failure of his proposed reintegration of the two entities last year following shareholder resistance. Succeeding Roost at Sulzer Medica is Max Link, current Sulzer Medica vice-chairman. Link formerly served as CEO of Corange Ltd. and Sandoz Pharma. Leonardo Vannotti will serve as the new chairman of Sulzer Ltd. The firm will seek to prevent election of board members nominated by shareholder InCentive Capital AG at its April 19 annual general meeting to prevent furtherance of an unwelcome takeover attempt. A spin-off of Sulzer Medica is anticipated in the third quarter

Table

View full table

Tags:
Latest Headlines

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

Epitel Gets 510(k) Clearance On Remote EEG Technology

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

See All
UsernamePublicRestriction

Register

MT014695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By